Royal Victoria Eye And Ear Hospital

This site is conducting clinical research in eye diseases and neoplastic conditions, with studies focused on improving care for open-angle glaucoma, ocular hypertension, and selected choroidal melanoma cases. The trials are designed to assess how well new or emerging treatments can help preserve vision, manage eye pressure, and support better disease control.

• Evaluating a new approach to lowering intraocular pressure in people with open-angle glaucoma and ocular hypertension.
• Studying treatment effectiveness and safety for primary indeterminate lesions and small choroidal melanoma.
• Exploring a gene therapy strategy for advanced rod-cone dystrophy to assess its potential to support retinal function.

The research reflects a strong focus on both common and rare ophthalmic disorders, combining efforts to improve symptom control, evaluate safety, and advance more targeted eye treatments.

Clinical trials in this area are centered on open-angle glaucoma and ocular hypertension, two conditions where controlling eye pressure is critical to protecting vision. The work aims to test whether newer therapies can provide sustained pressure reduction for patients who are not well managed with standard eye drops.

• Assessing the lasting IOP-lowering effect of a sustained-release treatment for glaucoma and ocular hypertension.
• Focusing on people who need alternatives because of tolerance or adherence challenges with current therapy.
• Supporting better long-term management of vision-threatening eye disease.

This research area highlights practical treatment improvement, with an emphasis on maintaining pressure control and reducing the burden of ongoing eye-drop use.

The site is also involved in trials for eye tumors, particularly primary indeterminate lesions and small choroidal melanoma. These studies are intended to determine whether new treatments can safely and effectively manage early or limited forms of ocular cancer while helping preserve the eye and vision.

• Comparing an investigational therapy with sham control for small choroidal melanoma.
• Evaluating both safety and treatment effectiveness in ocular oncology.
• Advancing options for patients with lesions that require careful monitoring and targeted care.

Research in this field combines cancer treatment evaluation with eye-sparing goals, making it an important part of the hospital’s clinical trial portfolio.

Another area of investigation at the Royal Victoria Eye And Ear Hospital involves advanced rod-cone dystrophy, a rare inherited retinal disorder that can cause severe vision loss. The trial activity in this field is focused on testing a gene therapy approach to see whether it may be safe and potentially beneficial for people with advanced disease.

• Studying a new gene-based treatment for rod-cone dystrophy.
• Assessing safety, tolerability, and possible vision-related benefit.
• Contributing to research on rare retinal degeneration and future therapeutic options.

This work reflects growing interest in precision therapies for inherited eye disease, where the goal is to slow progression and improve outcomes for patients with limited current treatment options.